These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 37953690)

  • 1. Population Pharmacokinetics of Tenofovir Alafenamide Fumarate and Its Metabolite Tenofovir in Healthy Chinese Volunteers.
    Ji X; Li Y; Wang Z; Gao Y; Wang L
    Clin Pharmacol Drug Dev; 2024 Feb; 13(2):168-179. PubMed ID: 37953690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of P-glycoprotein and Cotreatment with Sofosbuvir on the Intestinal Permeation of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide Fumarate.
    Huliciak M; Lhotska I; Kocova-Vlckova H; Halodova V; Dusek T; Cecka F; Staud F; Vokral I; Cerveny L
    Pharm Res; 2023 Sep; 40(9):2109-2120. PubMed ID: 37594591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tenofovir alafenamide fumarate.
    Lee WA; Cheng AK
    Antivir Ther; 2022 Apr; 27(2):13596535211067600. PubMed ID: 35499175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection.
    Kayes T; Crane H; Symonds A; Dumond J; Cottrell M; Di Girolamo J; Manandhar S; Lim TH; Gane E; Kashuba A; Levy MT
    Aliment Pharmacol Ther; 2022 Aug; 56(3):510-518. PubMed ID: 35599363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma and intracellular pharmacokinetics of tenofovir in patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.
    Podany AT; Bares SH; Havens J; Dyavar SR; O'Neill J; Lee S; Fletcher CV; Swindells S; Scarsi KK
    AIDS; 2018 Mar; 32(6):761-765. PubMed ID: 29334548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tenofovir and emtricitabine concentrations in hair are comparable between individuals on tenofovir disoproxil fumarate versus tenofovir alafenamide-based ART.
    Okochi H; Louie A; Phung N; Zhang K; Tallerico RM; Kuncze K; Spinelli MA; Koss CA; Benet LZ; Gandhi M
    Drug Test Anal; 2021 Jul; 13(7):1354-1370. PubMed ID: 33742745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase I Evaluation of the Pharmacokinetics and Tolerability of the HIV-1 Maturation Inhibitor GSK3640254 and Tenofovir Alafenamide/Emtricitabine in Healthy Participants.
    Pene Dumitrescu T; Joshi SR; Xu J; Zhan J; Johnson M; Butcher L; Zimmerman E; Webster L; Davidson AM; Lataillade M; Min S
    Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33753329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Lymphoid Tissue Pharmacokinetics of Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide in HIV-Infected Persons.
    Fletcher CV; Podany AT; Thorkelson A; Winchester LC; Mykris T; Anderson J; Jorstad S; Baker JV; Schacker TW
    Clin Pharmacol Ther; 2020 Nov; 108(5):971-975. PubMed ID: 32385902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interspecies Differences in Tenofovir Alafenamide Fumarate Stability in Plasma.
    Parsons TL; Gwenden KN; Marzinke MA
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32540983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and efficacy of topical inserts containing tenofovir alafenamide fumarate and elvitegravir administered rectally in macaques.
    Makarova N; Singletary T; Peet MM; Mitchell J; Holder A; Dinh C; Agrahari V; Mendoza M; Pan Y; Heneine W; Clark MR; García-Lerma JG; Smith JM; Doncel GF
    EBioMedicine; 2022 Dec; 86():104338. PubMed ID: 36343572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An LC-MS/MS method for determination of tenofovir (TFV) in human plasma following tenofovir alafenamide (TAF) administration: Development, validation, cross-validation, and use of formic acid as plasma TFV stabilizer.
    Xiao D; Ling KHJ; Tarnowski T; Majeed SR; German P; Kearney BP; Zhao Y; Chen YS; Ma L; Zhang T
    Anal Biochem; 2020 Mar; 593():113611. PubMed ID: 32035040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and Safety of Tenofovir Alafenamide in HIV-Uninfected Subjects with Severe Renal Impairment.
    Custodio JM; Fordyce M; Garner W; Vimal M; Ling KH; Kearney BP; Ramanathan S
    Antimicrob Agents Chemother; 2016 Sep; 60(9):5135-40. PubMed ID: 27216057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tenofovir Alafenamide Plasma Concentrations Are Reduced in Pregnant Women Living With Human Immunodeficiency Virus (HIV): Data From the PANNA Network.
    Bukkems VE; Necsoi C; Hidalgo Tenorio C; Garcia C; Alba Alejandre I; Weiss F; Lambert JS; van Hulzen A; Richel O; Te Brake LHM; van der Meulen E; Burger D; Konopnicki D; Colbers A
    Clin Infect Dis; 2022 Sep; 75(4):623-629. PubMed ID: 34864950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Tenofovir alafenamide fumarate - a new generation of tenofovir].
    Snopková S; Havlíčková K; Husa P
    Klin Mikrobiol Infekc Lek; 2016 Sep; 22(3):111-117. PubMed ID: 27907972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF).
    De Clercq E
    Biochem Pharmacol; 2016 Nov; 119():1-7. PubMed ID: 27133890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population Pharmacokinetic Analysis of Darunavir and Tenofovir Alafenamide in HIV-1-Infected Patients on the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen (AMBER and EMERALD Studies).
    Ackaert O; McDougall D; Pérez-Ruixo C; Pérez-Ruixo JJ; Jezorwski J; Crauwels HM
    AAPS J; 2021 Jun; 23(4):82. PubMed ID: 34100149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus.
    Ray AS; Fordyce MW; Hitchcock MJ
    Antiviral Res; 2016 Jan; 125():63-70. PubMed ID: 26640223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tenofovir alafenamide (TAF) does not deplete mitochondrial DNA in human T-cell lines at intracellular concentrations exceeding clinically relevant drug exposures.
    Stray KM; Park Y; Babusis D; Callebaut C; Cihlar T; Ray AS; Perron M
    Antiviral Res; 2017 Apr; 140():116-120. PubMed ID: 28131805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tenofovir alafenamide use in pregnant and lactating women living with HIV.
    Eke AC; Brooks KM; Gebreyohannes RD; Sheffield JS; Dooley KE; Mirochnick M
    Expert Opin Drug Metab Toxicol; 2020 Apr; 16(4):333-342. PubMed ID: 32125906
    [No Abstract]   [Full Text] [Related]  

  • 20. Antiviral activity of tenofovir alafenamide (TAF) against HIV-1 clinical isolates harboring K65R.
    Cox S; Margot N; Callebaut C
    J Med Virol; 2023 Apr; 95(4):e28723. PubMed ID: 37185867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.